BREAKING! The World’s First Truly Non-Invasive Continuous Glucose Monitor, GlucoRx BioXensor Set For Launch In Europe In Early 2023.
Source: Medical Devices - Non-Invasive Continuous Glucose Monitor Sep 05, 2022 2 years, 2 months, 2 weeks, 3 days, 10 hours, 17 minutes ago
Medical Devices: GlucoRx Ltd, a medical technology company based in Surrey, United Kingdom that specializes in home use glucose monitoring devices for diabetics along with Cardiff University are on schedule to launch the world’s first truly non-invasive continuous glucose monitor in Europe by early 2023. The product will then be launched in the Asia-Pacific region by mid-2023 and subsequently in the United States, Canada and South America by the end of 2023.
The launch of the device called the GlucoRx BioXensor will herald a new era of needle-free monitoring for individuals with diabetes.
The new GlucoRx BioXensor utilizes radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute.
The GlucoRx BioXensor is also one of the only portable home use
Medical Devices that is also able to supply a wide parameter of important clinical data such as Sp02, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection beside blood glucose levels due to the multiple sensors in the device.
At present, data supplied by the World health Organization or WHO shows approximately 422 million individuals around the globe have diabetes.
https://www.who.int/health-topics/diabetes#tab=tab_1
In America alone, there are more than 34.2 million individuals of all ages or about 10.5% of the population that has diabetes according to a 2018 U.S. CDC Report.
https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
The number of individuals who will develop diabetes is expected to rise exponentially in the next few years especially with the ongoing COVID-19 pandemic as studies have shown that SARS-CoV-2 infections also contribute to the onset of diabetes!
https://www.thailandmedical.news/news/german-study-warns-that-even-mild-sars-cov-2-infections-are-triggering-new-onset-type-2-diabetes-in-many
https://www.thailandmedical.news/news/study-warns-of-an-emerging-surge-in-diabetes-in-otherwise-healthy-individuals-as-a-result-of-covid-19
https://www.thailandmedical.news/news/covid-19-news-doctors-worldwide-are-reporting-increases-of-new-onset-diabetes-cases-most-probably-triggered-by-covid-19
st-time-can-be-due-to-high-ace2-expression-in-pancreatic-islet-cells-during-in">https://www.thailandmedical.news/news/covid-19-research-cases-of-covid-19-patients-developing-diabetes-for-first-time-can-be-due-to-high-ace2-expression-in-pancreatic-islet-cells-during-in
https://www.thailandmedical.news/news/breaking-covid-19-latest-study-shows-patients-not-previously-diagnosed-with-diabetes-exhibiting-hyperglycemia-and-increased-mortality
https://www.thailandmedical.news/news/breaking-diabetes-and-covid-19-german-case-study--confirms-that-sars-cov-2-can-trigger-diabetes-in-young--adults-otherwise-healthy
https://www.thailandmedical.news/news/breaking-u-s-cdc-reports-high-incidences-of-kidney-failure,-clots,-diabetes-and-heart-issues-in-post-covid-children-and-teenagers
https://www.thailandmedical.news/news/breaking-covid-19-and-children-uk-researchers-warn-that-covid-19-could-be-linked-to-onset-of-type-one-diabetes-and-diabetic-ketoacidosis-in-children
https://www.thailandmedical.news/news/covid-19-triggers-hyperglycemia-and-also-disrupts-fat-cells-and-causes-decreased-production-of-the-hormone-adiponectin-especially-in-severe-stages
At present, individuals with diabetes must prick their finger to extract and test their blood several times a day using glucometers or apply semi-invasive devices such as continuous blood glucose monitors (CGMs).
To date, there is no non-invasive glucose monitors in the market.
The novel GlucoRx BioXensor is the first to provides individuals with an alternative to blood glucose monitoring for the first time by measuring levels from 3mmol/l to 30 mmol/l.
The device is not only small and discreet, but the wearable multi-sensor device just weighs 14g and is 42mm in diameter by 7mm and is simply stuck to the body.
The GlucoRx BioXensor was developed in collaboration with Professor Adrian Porch and Dr Heungjae Choi, who are both experts in radio frequency technology from Cardiff University’s School of Engineering.
According to the developers, when used as an early intervention to change lifestyle, the GlucoRx BioXensor will assist in preventing the onset of diabetes, or its remission, and improve quality of life with its smart alarms and remote monitoring technology.
GlucoRx chief operating officer, Chris Chapman told Thailand
Medical News, “We are excited about this life-changing end-to-end diabetes monitoring platform of ours which can be discreetly stuck on the skin to monitor blood glucose, giving readings every minute on smart mobile applications. GlucoRx BioXensor has standout accuracy with a proven MARD of 10.4%, owing to its multi sensor approach capturing blood glucose as well as Sp02, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. The wearable device has a longer shelf-life because it is not chemical in its action.”
The expected starting retail price of the device is about US$640 according to sources involved with its launch.
The device has already been used in a beta-testing campaign involving several clinics and doctors and even Thailand Medical News that had a chance to allow some of our readers to beta-test the device found it to be extremely accurate and also very easy to use with no complication, pain or mess and possible blood contamination that is typically associated with the existing glucose monitors.
The device has already been tested in several successful clinical trials at Swansea University-UK with Professor Dr Stephen Luzio.
A few more trails are currently underway and the product has already been submitted for EU CE Certification.
For the latest on new
Medical Devices, keep on logging to Thailand
Medical News.
Share
Tweet
Share
